Olanzapin Biomo (Olanzapine)

Olanzapine, the active ingredient in Olanzapin Biomo, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Olanzapin Biomo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olanzapin Biomo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric disorders. - Schizophrenia: helps reduce positive and negative symptoms and prevents relapse. - Bipolar I disorder: aids ​     ​  ​  ​  stabilisation  ​   ​  of mood  ​  ​  ​  episodes  ​  ​  ​  including  ​  ​  ​  mania  ​ ​  and  ​ depressive  ​ phases. - Psychotic depression: improves depressive symptoms when psychotic features are present. - Acute agitation: provides rapid calming ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

Olanzapine may produce a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being overly tired. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: rise in blood lipid levels. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, especially of the face. - Hyperglycaemia: significant increase ​ ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Agranulocytosis: dangerously low white‑blood‑cell count. - Seizures: new‑onset or worsening of existing seizure activity. - Severe hypersensitivity: rash, angio‑edema, or anaphylaxis. - Cardiac arrhythmias: QT‑interval prolongation leading to irregular heartbeats. - Hepatotoxicity: elevated liver enzymes or liver injury.

Olanzapine requires                      …  …  ...     ​   …  ​  ​ …  ...  

t  ​   t ​  ​  … … 

   t   ewline